Assetmark Inc. Has $131.99 Million Stock Position in Exelixis, Inc. $EXEL

Assetmark Inc. grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1,230.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,195,971 shares of the biotechnology company’s stock after acquiring an additional 2,955,813 shares during the period. Assetmark Inc. owned 1.19% of Exelixis worth $131,994,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Illinois Municipal Retirement Fund boosted its stake in Exelixis by 19.1% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 204,211 shares of the biotechnology company’s stock valued at $8,434,000 after purchasing an additional 32,737 shares during the period. Westover Capital Advisors LLC lifted its holdings in shares of Exelixis by 61.4% during the third quarter. Westover Capital Advisors LLC now owns 77,035 shares of the biotechnology company’s stock worth $3,182,000 after buying an additional 29,316 shares in the last quarter. Caprock Group LLC bought a new stake in shares of Exelixis in the third quarter valued at about $346,000. Krilogy Financial LLC grew its stake in shares of Exelixis by 98.7% in the third quarter. Krilogy Financial LLC now owns 20,564 shares of the biotechnology company’s stock valued at $830,000 after acquiring an additional 10,215 shares in the last quarter. Finally, Stratos Wealth Partners LTD. increased its position in Exelixis by 10.9% during the third quarter. Stratos Wealth Partners LTD. now owns 7,456 shares of the biotechnology company’s stock worth $308,000 after acquiring an additional 730 shares during the period. Institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Truist Financial set a $51.00 price objective on shares of Exelixis in a report on Wednesday, January 14th. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Barclays increased their price target on Exelixis from $41.00 to $44.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. UBS Group set a $41.00 price objective on Exelixis in a report on Monday, January 5th. Finally, HC Wainwright increased their target price on Exelixis from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $47.11.

Key Headlines Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 EPS beat and shareholder returns — Exelixis reported $0.94 EPS vs. ~$0.74 consensus and repurchased $264.5M of stock, improving profitability metrics and returning capital to shareholders. Exelixis Reports Solid Earnings
• Positive Sentiment: Zanzalintinib upside — Management is positioning for a potential 2026 launch (PDUFA Dec. 3, 2026) for zanzalintinib in colorectal cancer, which the company cites as a multi‑billion dollar peak-sales opportunity and core to its franchise growth thesis. Pipeline & Franchise Strategy
• Positive Sentiment: Analyst upward moves — Royal Bank of Canada nudged its price target to $46 (sector perform), and Barclays has also raised targets recently, signaling some analyst confidence in the growth story. Analyst Note
• Neutral Sentiment: Core revenue driver — Cabometyx remains the primary revenue engine (franchise sales cited at ~$2.12B) and management guided 2026 revenue to $2.52–2.62B excluding potential zanzalintinib sales. Growth Strategy
• Neutral Sentiment: Supporting disclosure — Full earnings call transcript, presentation and analyst writeups are available for deeper due diligence. Earnings Presentation Call Transcript
• Neutral Sentiment: Short-interest data appears anomalous (reports showing 0 shares); treat as unreliable until corrected by exchanges/clearing agents.
• Negative Sentiment: Revenue miss and conservative baseline guidance — Q4 revenue ($598.7M) came in below the ~$609M consensus and 2026 guidance excludes potential zanzalintinib revenue, creating near‑term uncertainty and prompting profit-taking. Zacks Earnings Coverage
• Negative Sentiment: Mixed analyst stance — Wells Fargo raised its target to $35 but maintains an Equal Weight stance, which implies limited near‑term upside and contrasts with higher targets from other shops; this divergence contributes to volatile near-term sentiment. Wells Fargo Note

Exelixis Price Performance

Shares of NASDAQ EXEL opened at $42.70 on Friday. The company has a 50 day simple moving average of $43.63 and a 200 day simple moving average of $40.95. Exelixis, Inc. has a 1 year low of $32.38 and a 1 year high of $49.62. The firm has a market cap of $11.09 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 0.73 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.55 earnings per share. As a group, research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 34,187 shares of Exelixis stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $41.88, for a total transaction of $1,431,751.56. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 72,230 shares of company stock worth $3,046,923. 2.82% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.